ADC payloads to Fc mutations: advancing bioanalysis for novel modalities
Thursday 23 October 2025
07:00 [PDT] 09:00 [CDT] 15:00 [BST]
Optimizing bioanalytical strategies for complex antibody-based therapeutics.
When working with bioanalytical antibodies for challenging targets you want to rely on high-quality, reproducible results. Bio-Rad’s (CA, USA) scientists have developed custom and catalog antibodies against different types of biologics, including complex targets such as bispecifics, antibody-drug conjugates (ADCs) and Fc mutations (e.g., YTE). Their industry-leading set of bioanalytical solutions, built on over 20 years of experience, helps you build confidence in your results.
What will you learn?
- How antibody phage display enables precise and efficient antibody generation for critical reagents to be used in bioanalysis
- Design strategies for anti-diotype antibodies to ADC payloads
- Insights into generating antibodies ADC and payload monomethyl auristatin E
- How SpyTag technology enables TrailBlazer platform for rapid format switching
Who may this interest?
- Scientists in bioanalysis, drug development and biosimilar development
- In vitro diagnostics scientists and academic researchers
Paul Royle
EMEA Custom Antibody and Northern Europe Biopharma Sales Manager
Bio-Rad (CA, USA)
Paul Royle is a technical sales manager for Bio-Rad’s Custom Discover and Tool Antibody Services in Europe (Pioneer and HuCAL®) and has been with Bio-Rad’s antibody division for over 12 years. Prior to this he worked in an immunology diagnostics company for almost 7 years. Paul holds a degree and PhD from the University of Nottingham (UK) and has post-doctoral research experience from the University of Warwick (UK).
In association with:
